durvalumab and tremelimumab market size forecast and emerging insight

“Durvalumab and Tremelimumab Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about Durvalumab and Tremelimumab for Urothelial Carcinoma (UCC) in the seven major markets. A detailed picture of the Durvalumab and Tremelimumab for UCC in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the Durvalumab and Tremelimumab for UCC. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Durvalumab and Tremelimumab market forecast analysis for UCC in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in UCC.

Drug Summary

IMFINZI (durvalumab) is an intravenously administered human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses. It is approved for non-small cell lung cancer (NSCLC): for treatment of unresectable, Stage II or III NSCLC that has not progressed following concurrent platinum-based chemotherapy and radiation therapy, extensive-stage small cell lung cancer (ES-SCLC): for first-line treatment in combination with etoposide and either carboplatin or cisplatin followed by single-agent maintenance, hepatocellular carcinoma: for first-line single-agent treatment of unresectable or metastatic hepatocellular carcinoma and in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).

IMJUDO (tremelimumab) is a human monoclonal antibody that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo blocks the activity of CTLA-4, contributing to T-cell activation, priming the immune response to cancer, and fostering cancer cell death. Currently, the company is conducting a Phase III (NILE) trial to evaluate the efficacy and safety of combining durvalumab ± tremelimumab with standard-of-care (SoC) chemotherapy (cisplatin  + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), the results are anticipated to be out in H2 2023.

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the Durvalumab and Tremelimumab description, mechanism of action, dosage and administration, research and development activities in Urothelial Carcinoma (UCC).
• Elaborated details on Durvalumab and Tremelimumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Durvalumab and Tremelimumab research and development activities in UCC across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Durvalumab and Tremelimumab.
• The report contains forecasted sales of Durvalumab and Tremelimumab for UCC till 2032.
• Comprehensive coverage of the late-stage emerging therapies for UCC.
• The report also features the SWOT analysis with analyst views for Durvalumab and Tremelimumab in UCC.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Durvalumab and Tremelimumab Analytical Perspective by DelveInsight

In-depth Durvalumab and Tremelimumab Market Assessment

This report provides a detailed market assessment of Durvalumab and Tremelimumab for Urothelial Carcinoma (UCC) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

Durvalumab and Tremelimumab Clinical Assessment

The report provides the clinical trials information of Durvalumab and Tremelimumab for Urothelial Carcinoma (UCC) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

• In the coming years, the market scenario for Urothelial Carcinoma (UCC) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Durvalumab and Tremelimumab dominance.
• Other emerging products for UCC are expected to give tough market competition to Durvalumab and Tremelimumab and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Durvalumab and Tremelimumab in UCC.
• Our in-depth analysis of the forecasted sales data of Durvalumab and Tremelimumab from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Durvalumab and Tremelimumab in UCC. 

Key Questions

• What is the product type, route of administration and mechanism of action of Durvalumab and Tremelimumab?
• What is the clinical trial status of the study related to Durvalumab and Tremelimumab in Urothelial Carcinoma (UCC) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Durvalumab and Tremelimumab development?
• What are the key designations that have been granted to Durvalumab and Tremelimumab for UCC?
• What is the forecasted market scenario of Durvalumab and Tremelimumab for UCC?
• What are the forecasted sales of Durvalumab and Tremelimumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to Durvalumab and Tremelimumab for UCC?
• Which are the late-stage emerging therapies under development for the treatment of UCC?